Significant elevation of the mRNA expressions of PDGFB, VEGFR2, FGFR1, and FGFR2 in the ulcer margin was noted compared to the non-ulcer areas (p<0.05) in the non-cirrhotic group, but not in the cirrhotic group.

<p>Significant elevation of the mRNA expressions of PDGFB, VEGFR2, FGFR1, and FGFR2 in the ulcer margin was noted compared to the non-ulcer areas (p<0.05) in the non-cirrhotic group, but not in the cirrhotic group.</p

Demographic data between cirrhotic patients with gastric ulcers and non-cirrhotic patients with gastric ulcers.

<p>Value are means ± S.D.</p

The mRNA expressions of proangiogenic growth factors (VEGF, bFGF, PDGF) and their receptors (VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRA, PDGFRB) in gastric ulcer margins between the cirrhotic and non-cirrhotic groups.

<p>The mRNA expressions of proangiogenic growth factors (VEGF, bFGF, PDGF) and their receptors (VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRA, PDGFRB) in gastric ulcer margins between the cirrhotic and non-cirrhotic groups.</p

Compare the expression of proangiogenic growth factors (VEGF, bFGF, PDGF) and their receptors (VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRA, PDGFRB) over the non-ulcer part and ulcer margin of gastric mucosa.

<p>VEGF: vascular endothelial growth factor, VEGFR1: VEGF receptor 1, VEGFR2: VEGF receptor 2, PDGFA: platelet derived growth factor A, PDGFRA: PDGF receptor A, PDGFRB: PDGF receptor B, bFGF: basic fibroblast growth factor, FGFR1: fibroblast growth factor receptor 1, FGFR2: FGF receptor 2.</p><p>GAPDH : glyceraldehydes- 3-phosphate dehydrogenase Value is means ± S.D.</p

The mRNA expression of proangiogenic growth factors (VEGF, bFGF, PDGF) and their receptors (VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRA, PDGFRB) over the non-ulcer part of gastric mucosa.

<p>VEGF: vascular endothelial growth factor, VEGFR1: VEGF receptor 1, VEGFR2: VEGF receptor 2, PDGFA: platelet derived growth factor A, PDGFRA: PDGF receptor A, PDGFRB: PDGF receptor B, bFGF: basic fibroblast growth factor, FGFR1: fibroblast growth factor receptor 1, FGFR2: FGF receptor 2.</p><p>GAPDH : glyceraldehydes- 3-phosphate dehydrogenase Value is means ± S.D.</p

Independent predictors of new-onset atrial fibrillation in patients with gastroesophageal reflux disease according to proton pump inhibitor use.

<p>CI, confidence interval; HR, hazard ratio; PPIs, proton pump inhibitors.</p><p>Adjusted for age, sex, hypertension, diabetes mellitus, hyperlipidemia, congestive heart failure, coronary artery disease, ischemic stroke, chronic obstructive pulmonary disease, and thyrotoxicosis.</p

Demographic data on patients with and without gastroesophageal reflux disease.

<p>GERD, gastroesophageal reflux disease.</p

Independent predictors of new-onset atrial fibrillation.

<p>AF, atrial fibrillation; CI, confidence interval; GERD, gastroesophageal reflux disease; HR, hazard ratio.</p><p>Adjusted for age, sex, hypertension, diabetes mellitus, hyperlipidemia, congestive heart failure, coronary artery disease, ischemic stroke, chronic obstructive pulmonary disease, and thyrotoxicosis.</p

Kaplan-Meier curves of the freedom from atrial fibrillation (AF) in the patients.

<p>Group 1 included patients with gastroesophageal reflux disease (GERD), and group 2 included patients without GERD. There was a statistically significant difference between the two curves (log-rank test, <i>p</i> = 0.024).</p

Multivariate logistic analysis of risk factors for antimicrobial resistance.

<p>CLA: clarithromycin; LEV: levofloxacin; MET: metronidazole; AMO: amoxicillin; TET: tetracycline.</p><p>Multivariate logistic analysis of risk factors for antimicrobial resistance.</p